Lymphoma diagnosis: an update.

Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 2004;15:1623–32. 24 Bokemeyer C, Aapro MS, Courdi A et al; European Organisation for Research and Treatment of Cancer (EORTC). Taskforce for the Elderly. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Review. Eur J Cancer 2007;43:258–70. 25 Rizzo JD, Seidenfeld J, Piper M et al. Erythropoietin: a paradigm for the development of practice guidelines. Hematology Am Soc Hematol Educ Programme 2001:10–30. 26 Greaves P, Agrawal S, Lim C, Poole C. Intravenous iron improves response rates to recombinant human erythropoetin in anaemic patients with haematological malignancy on chemotherapy: which iron parameters to use? Haematologica 2007; 92(S1):abstract 0078. 27 US Food and Drug Administration (FDA). FDA Alert. Information on Erythropoiesis Stimulating Agents (ESA) (marketed as Procrit, Epogen, and Aransep). Rockville, MD: FDA. Updated 9 March 2007. www.fda.gov/cder/drug/infopage/RHE/def ault.htm